GH
Guardant Health, Inc. Health Care Services-Medical Laboratories Russell 3000
$178.80Close
$23.4BMarket cap
$78.60 – $187.2252-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 96 · stronger than 96% of stocks over 12 months
- Near its high 4% below its 52-week high
Cautions
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
4%
1wk
up 5.7%
price change
1mo
up 0.2%
price change
12-month return
up 93%
market up 11% ·
its own up 137%
F-score
4 / 9
Weak
Altman Z″
-2.57
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 1.8%
EBIT / enterprise value
Cheaper than
19%
of the market · expensive
Revenue growth
up 33%
year on year
EPS growth
—
latest quarter
Sales growth
up 44%
latest quarter · -4 pts
ROE
—
return on equity
Free cash margin
down 24%
-$233.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- took on more long-term debt
- issued more shares
- profits backed by cash
- short-term liquidity improved
- gross margin widened
- assets working harder
Repair signals
- Gross margin 60.8% → 64.5%
Trade setup
ATR%
4.7%
$8.48 a day · 2×ATR $161.84
RS
96 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.8×
vs 50-day average
Up/down volume
1.15
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$99.3M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 5.4% over the year, from 124m to 131m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Jul 30, 2026
Financials
- Gross 64%
- Net -42%
- Free cash -24%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $286.7M | $373.7M | $449.5M | $563.9M | $739.0M | $982.0M |
| Gross margin | — | — | — | 60% | 61% | 64% |
| Operating income | -$254.9M | -$411.0M | -$544.4M | -$564.7M | -$443.6M | -$437.2M |
| Net income | -$246.3M | -$384.8M | -$654.6M | -$479.4M | -$436.4M | -$416.3M |
| Net margin | -86% | -103% | -146% | -85% | -59% | -42% |
| Earnings per share | -$2.53 | -$3.80 | -$6.41 | -$4.28 | -$3.56 | -$3.32 |
| Free cash flow | -$140.1M | -$284.1M | -$386.9M | -$345.5M | -$274.9M | -$233.1M |
| Free cash margin | -49% | -76% | -86% | -61% | -37% | -24% |
| Cash | $833.0M | $492.2M | $141.6M | $1.1B | $525.5M | $378.2M |
| Long-term debt | — | — | — | — | $1.1B | $1.5B |
| Shareholders' equity | $1.3B | $645.0M | $60.2M | $158.7M | -$139.6M | -$99.3M |
| Shares outstanding | 100.21m | 101.77m | 102.62m | 121.63m | 123.99m | 130.64m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Oct 29, 2025 | Quarterly ↗ | Sep 30, 2025 | 29d |
| Jul 30, 2025 | Quarterly ↗ | Jun 30, 2025 | 30d |
| Apr 30, 2025 | Quarterly ↗ | Mar 31, 2025 | 30d |
| Feb 20, 2025 | Annual ↗ | Dec 31, 2024 | 51d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Jul 30, 2026 | Results ↗ |
| Jun 18, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 27, 2026 | Director or officer change ↗ |
| Feb 19, 2026 | Results ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Nov 7, 2025 | Material agreement · New obligation · Unregistered share sale · Other events ↗ |
| Oct 29, 2025 | Results ↗ |
| Sep 24, 2025 | Regulation FD ↗ |
| Sep 15, 2025 | Director or officer change ↗ |
| Jul 30, 2025 | Results ↗ |
| Jun 20, 2025 | Shareholder vote ↗ |